Infringement Analysis in Basel.

A patent infringement analysis Basel companies can rely on has to reach deep into the chemistry, pharmacology and biologics literature, because that is where the region’s inventive record and its prior art actually live. Basel is the densest pharmaceutical and life-sciences cluster in the world — Roche and Novartis are headquartered here, alongside a tri-border web of chemical, biotech and generic manufacturers that reaches into Germany and France.

Those portfolios are litigated in a forum unlike any in the European Union. Switzerland runs its own specialised Federal Patent Court (Bundespatentgericht / Tribunal fédéral des brevets) in St. Gallen, which holds exclusive national jurisdiction over patent infringement and validity, with appeals to the Swiss Federal Supreme Court in Lausanne. Critically, Switzerland is not in the EU and not in the Unified Patent Court, so a Basel patent is litigated separately from the rest of Europe. PerspireIP builds the technical infringement and validity analysis those disputes turn on.

Where a patent infringement analysis Basel case is heard

Switzerland concentrates all patent disputes in one specialised court. The Federal Patent Court (Bundespatentgericht), whose seat is in St. Gallen, has exclusive first-instance jurisdiction over patent infringement actions, validity challenges and preliminary injunctions across the whole country. There is no patent forum in Basel, in Zurich or in any cantonal court: a Basel pharmaceutical or chemistry company sued over a Swiss patent — or the Swiss validation of a European patent — defends that case in St. Gallen.

The court is deliberately built for technical cases. Its panels combine legally trained judges with technically qualified judges — chemists, pharmacologists, engineers — who read the patents themselves rather than relying solely on party experts. Infringement and validity are decided together in a single, integrated proceeding, which avoids the German-style split between an infringement court and a separate nullity court. That unified model means a defendant’s non-infringement and invalidity arguments are weighed side by side, and it rewards an analysis that addresses both from the start.

• Federal Patent Court, St. Gallen — sole national forum for Swiss patent infringement and validity, with legally and technically trained judges
• Swiss Federal Supreme Court, Lausanne — the appellate court that reviews Federal Patent Court judgments
• Swiss Federal Institute of Intellectual Property (IPI/IGE) — the office that grants and administers Swiss patents
• Outside the UPC — Swiss rights are litigated separately from the Unified Patent Court and the EU

For a Basel litigant the effect is that the technical work is prepared in the city’s pharma-chemistry language but presented to a specialised court an hour east in St. Gallen, on a Swiss procedural calendar known for speed and for pragmatic case management. The party that arrives with a clean, well-dated claim mapping tends to set the tempo.

Basel’s pharma and chemistry engine: the claims behind the cluster

Basel is the highest-density pharmaceutical hub on earth, and the shape of its patents follows from that. Roche and Novartis run global research and development from the city, Lonza and a deep bench of contract manufacturers supply the value chain, and the tri-border region — touching Germany’s BASF and Boehringer footprint and neighbouring France — makes it Europe’s densest industrial life-sciences cluster. Five centuries of chemical and pharmaceutical industry have left an inventive record measured in the tens of thousands of patents.

That concentration defines the local litigation profile. A patent infringement analysis Basel matter rarely turns on a simple device; it turns on chemistry and biology — the structure of a molecule, the composition of a formulation, the sequence of a biologic, the steps of a synthesis. These claims are frequently written in functional or Markush terms, and reading them onto an accused product demands genuine subject-matter fluency.

• Small-molecule drug claims — active compounds, salts, polymorphs, formulations and methods of treatment
• Biologics — antibodies, fusion proteins and cell therapies, often claimed by function or by sequence
• Specialty and process chemistry — synthesis routes, catalysts, intermediates and manufacturing methods
• Diagnostics, delivery systems and combination products bridging pharma and medtech
• Second-medical-use and dosing-regimen claims that generate recurring validity disputes

For an infringement analyst, this means the decisive evidence is scientific. Establishing that an accused product practises a claimed compound, formulation or process often requires analytical chemistry — characterising a polymorph, confirming a synthetic route, sequencing a biologic — and the claim chart has to connect that laboratory evidence to the precise wording of the claim.

Switzerland is outside the UPC: why a Basel patent is litigated alone

This is the single most important structural fact for a Basel patent strategy. Switzerland is not a member of the European Union, and it is not part of the Unified Patent Court or the unitary patent system that launched across much of Europe in June 2023. A unitary patent has no effect in Switzerland, and the UPC has no jurisdiction over Swiss rights. The Swiss designation of a European patent stands as an independent national right, enforced and challenged only before the Federal Patent Court in St. Gallen.

For a Basel pharmaceutical or chemistry company with a pan-European product, that means litigation runs on two separate tracks. A competitor can attack the EU portion of a European patent at the UPC and, entirely separately, attack the Swiss designation in St. Gallen — two forums, two procedural regimes, two bodies of case law, and potentially two different outcomes on the same invention. A UPC revocation cannot touch the Swiss right, and a Swiss judgment does not bind the UPC.

The analytical consequence is that Switzerland has to be scoped as its own matter from the outset. A patent infringement analysis Basel engagement cannot simply be borrowed from a UPC filing; it has to account for Swiss claim-construction practice, the Federal Patent Court’s expectations, and the fact that the Swiss decision will be reached on its own timeline. Companies that treat Switzerland as an afterthought to a UPC case are the ones caught out.

Where pharmaceutical and chemistry infringement and prior-art evidence lives

Life-sciences and chemistry cases are heavy non-patent-literature terrain, on both the infringement and the validity side. Proving that an accused product reads on a claimed compound or formulation is an analytical-chemistry exercise, and the reference that anticipates or renders a claim obvious is frequently a journal paper, a conference abstract or a regulatory disclosure rather than another patent — and it may predate the asserted patent by years.

• Analytical characterisation — XRPD for polymorphs, chromatography and spectroscopy for composition, sequencing for biologics
• Chemical Abstracts Service (CAS) and STN for structure, reaction and Markush searching that keyword tools cannot replicate
• PubMed, MEDLINE and the primary journal literature across chemistry, pharmacology and molecular biology
• Conference proceedings and abstracts — ACS, AACR, ASH and similar meetings where results surface before publication
• Regulatory records — Swissmedic and EMA filings, labels and clinical-trial registrations with fixed public dates

Dating is where many searches fail. A journal article, a poster or a clinical-trial posting counts as prior art only if you can prove it was publicly available before the claim’s priority date. We treat public availability as evidence to be established, not assumed — capturing publication dates, indexing records and library or database receipts — so every reference survives a validity challenge before the Federal Patent Court.

Claim charts and evidence of use: the analysis methodology

A credible infringement analysis is built limitation by limitation, not on overall impression. We begin by construing each asserted claim the way the Federal Patent Court would — resolving the meaning of every term, including the functional and Markush language common in pharma and chemistry claims — and only then test the accused product against that construction. Each limitation gets its own row in a claim chart, matched to concrete evidence: an analytical result, a synthesis disclosure, a label, a measured property.

For chemistry and biologics claims that evidentiary chain is laboratory-grade. Showing that an accused product practises a claimed polymorph, salt or formulation can require characterisation data; showing infringement of a process claim can require reconstructing a synthetic route from intermediates and impurity profiles. Where a limitation is not met literally, we analyse infringement under the Swiss doctrine of equivalents, and we flag the limitations most exposed to a non-infringement or invalidity attack so counsel can see the weak seams first.

The deliverable is a document counsel can file and defend before the St. Gallen court: a limitation-by-limitation chart, a reasoned infringement position, the supporting exhibits, and a parallel validity read that anticipates the invalidity defence heard in the same integrated proceeding. Because Swiss proceedings move briskly, that package has to be substantially complete early, before a preliminary-injunction request or a complaint is filed.

Forum and strategy for a patent infringement analysis Basel matter

Strategy for a Basel dispute has to begin from Switzerland’s independence. Because the Swiss right lives or dies in St. Gallen regardless of what happens at the UPC, the two campaigns can be sequenced or run in parallel — and a patentee may win in one forum while losing in the other. A defendant with a strong validity case may push hard in Switzerland even while an EU-wide fight plays out separately; a patentee may use the Federal Patent Court’s speed to secure a preliminary injunction on a key market.

Those decisions ride on facts the infringement analysis surfaces: how literally the accused product reads on the claims, how the priority dates line up against the best prior art, and whether the strongest invalidity grounds are printed-publication art or use-based grounds. We build the analysis so it can support either a Swiss infringement action or a Swiss nullity action, and so it dovetails with — without being confused for — any parallel UPC or national European proceeding.

The Federal Patent Court also offers expedited nullity proceedings that can resolve validity quickly, which matters enormously for pharma and medtech portfolios where a single patent can gate a product. Knowing whether a patent is likely to survive such a challenge is exactly what a rigorous, evidence-backed validity read tells you before you commit to a forum.

How PerspireIP supports Basel litigants and their Swiss counsel

We work as the specialist technical arm behind your Swiss litigators. Basel law firms and in-house teams retain PerspireIP to turn dense pharmaceutical, biologic and chemistry patents into infringement and validity analysis their counsel can file and argue before the Federal Patent Court. We are fluent in the subject-matter the region produces — small molecules, antibodies, formulations, synthesis routes — and we search the non-patent literature where the decisive references usually hide.

• Element-by-element claim construction and infringement charts for small-molecule, biologic and chemistry patents
• Evidence-of-use development grounded in analytical chemistry — polymorph, composition, sequence and process characterisation
• Deep non-patent-literature invalidity searching across CAS/STN, PubMed, conference abstracts and regulatory records, every reference dated and defensible
• Analysis scoped as an independent Swiss matter, distinct from any parallel UPC or national European action
• Support for expedited nullity and preliminary-injunction strategy before the Federal Patent Court in St. Gallen

Whether you are defending a Basel pharma or chemistry company against an assertion, enforcing a Roche- or Novartis-scale portfolio, or scoping Switzerland alongside a wider European campaign, we scale to fit — a single-patent read, a multi-patent campaign or ongoing litigation support. Send us the patent number, the accused product and your key dates, and we will scope a patent infringement analysis Basel project within one business day, working confidentially alongside your Swiss counsel.

IP Landscape & Resources in Basel

Key intellectual-property authorities and venues relevant to Basel:

• Swiss Federal Institute of Intellectual Property (IPI/IGE) — the Swiss patent and trademark office, where Swiss patents are granted and administered
• Swiss Federal Patent Court (Bundespatentgericht) — the court in St. Gallen with exclusive national jurisdiction over Swiss patent infringement and validity
• Swiss Federal Supreme Court — the court in Lausanne that hears appeals from the Federal Patent Court

Request a Patent Infringement Analysis in Basel

Explore related PerspireIP services: Patent Infringement Analysis · Patent Invalidation · Prior Art Litigation Search.

Frequently Asked Questions